Aeterna Zentaris (AEZS) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results
August 9, 2016 4:30 PM EDTNear-Term Major Inflection Point Approaching with Expected Completion of two Pivotal Phase 3 Programs in 2016
All $ amounts are in US Dollars
Key developments
Product development programs on track towards FDA submission in 2017 Zoptrex (zoptarelin doxorubicin) pivotal Phase 3 clinical program remains on track for completion in 2016 Macrilen (macimorelin) confirmatory Phase 3 Trial for the evaluation of AGHD also remains on track for completion in 2016 Zoptrex out-licensing activity successfully continues Zoptrex licensee in China and related territories, Sinopharm A-Think... More